We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Curious about Edwards Lifesciences (EW) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Analysts on Wall Street project that Edwards Lifesciences (EW - Free Report) will announce quarterly earnings of $0.73 per share in its forthcoming report, representing an increase of 9% year over year. Revenues are projected to reach $1.68 billion, increasing 8% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Edwards Lifesciences metrics that are routinely monitored and predicted by Wall Street analysts.
Based on the collective assessment of analysts, 'Net Sales by Product Group- Transcatheter Mitral and Tricuspid Therapies' should arrive at $195.98 million. The estimate indicates a year-over-year change of +35%.
Analysts' assessment points toward 'Net Sales by Product Group- Surgical Structural Heart' reaching $267.05 million. The estimate indicates a change of +3.5% from the prior-year quarter.
According to the collective judgment of analysts, 'Net Sales by Product Group- Transcatheter Aortic Valve Replacement' should come in at $1.21 billion. The estimate indicates a change of +5.1% from the prior-year quarter.
Over the past month, shares of Edwards Lifesciences have returned +10.9% versus the Zacks S&P 500 composite's +0.7% change. Currently, EW carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Curious about Edwards Lifesciences (EW) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Analysts on Wall Street project that Edwards Lifesciences (EW - Free Report) will announce quarterly earnings of $0.73 per share in its forthcoming report, representing an increase of 9% year over year. Revenues are projected to reach $1.68 billion, increasing 8% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Edwards Lifesciences metrics that are routinely monitored and predicted by Wall Street analysts.
Based on the collective assessment of analysts, 'Net Sales by Product Group- Transcatheter Mitral and Tricuspid Therapies' should arrive at $195.98 million. The estimate indicates a year-over-year change of +35%.
Analysts' assessment points toward 'Net Sales by Product Group- Surgical Structural Heart' reaching $267.05 million. The estimate indicates a change of +3.5% from the prior-year quarter.
According to the collective judgment of analysts, 'Net Sales by Product Group- Transcatheter Aortic Valve Replacement' should come in at $1.21 billion. The estimate indicates a change of +5.1% from the prior-year quarter.
View all Key Company Metrics for Edwards Lifesciences here>>>Over the past month, shares of Edwards Lifesciences have returned +10.9% versus the Zacks S&P 500 composite's +0.7% change. Currently, EW carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .